| Date Filed | Type | Description |
| 08/25/2023 |
SC 13D
| First Light Asset Management, LLC reports a 19.7% stake in Societal CDMO, Inc. |
| 08/23/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results|
Docs:
|
"Societal CDMO Reports Second Quarter 2023 Financial Results Recorded Q2 Revenue of $21.8 Million Signed Multiple New Business Agreements with New and Existing Customers Secured Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement Agency; Allows Expansion into Manufacture of Psychedelic Drug Products Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO, CA, and GAINESVILLE, GA – August 14, 2023 — Societal CDMO, Inc. , a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the second quarter and six months ended June 30, 2023. “The second quarter was a highly productive period. During the quarter, we co...",
"FILLED CAPSULES ORAL LIQUIDS TABLETS OPHTHALMIC DROPPERS STERILE INJECTABLES TOPICALS" |
|
| 08/07/2023 |
SC 13G
| Cowen Prime Advisors LLC reports a 0% stake in RECRO PHARMA INC |
| 06/06/2023 |
SC 13G/A
| First Light Asset Management, LLC reports a 16% stake in Societal CDMO, Inc. |
| 05/26/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/18/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Societal CDMO Reports First Quarter 2023 Financial Results Recorded Q1 Revenue of $21.5 Million Signed Multiple New Business Agreements with New and Existing Customers Granted FDA Approval for Manufacture of First Commercial Tablet Product Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO, CA, and GAINESVILLE, GA – May 10, 2023 — Societal CDMO, Inc. , a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the first quarter ended March 31, 2023. “The company’s many achievements in 2022 placed Societal in an overall stronger financial position and paved the way for growth in 2023 and beyond. In the first quarter, we contin...",
"FILLED CAPSULES ORAL LIQUIDS TABLETS OPHTHALMIC DROPPERS STERILE INJECTABLES TOPICALS" |
|
| 04/06/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/24/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/24/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/01/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/01/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/01/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/01/2023 |
8-K
| Quarterly results|
Docs:
|
"Societal CDMO Reports Fourth Quarter and Full Year 2022 Financial Results Recorded Q4 Revenue of $24.3 Million, a 9% Increase Compared to Prior Year Period Clinical Trial Materials Development Business Grew by 58% in 2022; Significantly Expanded and Diversified Customer Base Executed Multi-Step Strategy Resulting in Reduction of Debt and Strengthened Financial Position Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO, CA, and GAINESVILLE, GA – March 1, 2023 — Societal CDMO, Inc. , a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the fourth quarter and year ended December 31, 2022. “One year ago, the company outlin...",
"FILLED CAPSULES ORAL LIQUIDS TABLETS OPHTHALMIC DROPPERS STERILE INJECTABLES TOPICALS" |
|
| 02/14/2023 |
SC 13G/A
| AWM Investment Company, Inc. reports a 10.5% stake in Societal CDMO, Inc. |
| 02/10/2023 |
SC 13G/A
| Samjo Capital LLC reports a 4.9% stake in Societal CDMO, Inc.1 |
| 01/05/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/03/2023 |
8-K
| Quarterly results |
| 12/20/2022 |
8-K
| Quarterly results |
| 12/16/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/13/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/13/2022 |
8-K
| Quarterly results |
| 12/13/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/12/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/12/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/12/2022 |
8-K
| Quarterly results |
| 11/16/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
|